Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 9NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Melanoma 7Sarcoma 6Gliosarcoma 6Glioblastoma 6Multiple Myeloma 5Hematologic Neoplasms 5Endometrial Neoplasms 5Carcinoma, Renal Cell 5Brain Neoplasms 5Rhabdomyosarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Tongue Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

Peripheral Blood Stem Cell Transplantation 10fludarabine phosphate 9Cyclophosphamide 9Filgrastim 8Busulfan 8Interferon-alpha 7Cytarabine 7Antilymphocyte Serum 7Radiotherapy 6Imatinib Mesylate 6Cyclosporine 6sargramostim 4Methylprednisolone 4Methotrexate 4Etoposide 4Tacrolimus 3Mycophenolic Acid 3Idarubicin 3Hydroxyurea 3Homoharringtonine 3Sunitinib 2Melphalan 2Ifosfamide 2Granulocyte-Macrophage Colony-Stimulating Factor 2Dasatinib 2Carboplatin 2Analgesia 2tipifarnib 1temsirolimus 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Chronic-Phase × Sirolimus × Clear all
NCT00101088 2013-01-14

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
21 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡